Given MLN4924 upregulated PD-L1 expression through activation of MEK, we hypothesized that this MLN4924 side-effect would compromise its anti-cancer activity, and by blocking PD-L1, MEK inhibitor or anti-PD-L1 antibody should overcome this side-effect. This evidence concerns the gene MAP2K7 and cancer.